Phase 1 N=17 BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) During 1st Course — 0; 3; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
N/A N=198 Lifestyle Intervention for Pakistani Women in Oslo
Metabolic Syndrome · Type 2 Diabetes
Primary: The Fasting Plasma Glucose Value, Baseline — 5.55; 5.53 mmol/L
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 3 N=183 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Infection, Human Immunodeficiency Virus
Primary: Mean Change From Baseline in Plasma HIV-1 RNA at Day 8 — -1.432 log10 copies/milliliter (mL) — p=<0.001
N/A N=23 Recovery of Visual Acuity in People With Vestibular Deficits
Vestibular Neuronitis · Vestibular Neuronitis, Bilateral · Vestibular Schwannoma
Primary: Change in Visual Acuity During Head Movement From Baseline to Discharge — 0.198; .296 LogMAR
N/A N=600 Prevent Return of Stroke Study
Stroke Recurrence · Transient Ischemic Attack
Primary: Blood Pressure — 76; 65 percentage of participants
N/A N=77 A Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain
Plantar Fasciitis
Primary: Heel Pain — 26.3; 27.9; 26.6; 23.9 score on a survey — p=0.78
N/A N=48 A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Survival — 270.5 days
Phase 3 N=1,116 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6 — 6.8; 14.5 percentage of participants — p=0.0206
N/A N=530 FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging
Fever
Primary: Fever >= 100.4 — 7.5; 37.6; 9.5 percentage of participants
Phase 1 N=12 Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Prostate Cancer
Primary: Number of Patients Experiencing Dose Limiting Toxicities (DLT's) — 1; 2 participants
Phase 3 N=416 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation — 12.1; 15.2 percentage of participants…
Phase 1 N=25 Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Glaucoma · Ocular Hypertension
Primary: Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax) — 0.0256; 0.0471; 0.0258; 0.0109 ng/mL
Phase 3 N=383 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Binge Eating Disorder
Primary: Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12) — -2.51; -3.87 Binge days per week — p=<0.001